Array BioPharma announced that it will present data from the Phase 3 COLUMBUS trial of encorafenib and binimetinib in advanced BRAF-mutant melanoma in an oral presentation on June 4, at the 54th Annual Meeting of the American Society of Clinical Oncology, or ASCO, in Chicago, Illinois.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.